Notably, the cytotoxicity of the most active compounds, VM26 and VM25, at an IC50 of 12.6 μM and 14.4 μM, respectively, is similar to that of gefitinib, a well-known anti-EGFR drug in cancer therapy, at an IC50 of 15.2 μM. This evidence concerns the gene EGFR and cancer.